Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis-Reference-Cited by-同舟云学术

Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis

Published:2023-10-25 Issue: Volume: Page:
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Abbad-Jaime de Aragón Carlota¹,Berna-Rico Emilio¹,Goas Almudena²,Pérez-Bootello Javier¹,Ballester-Martinez María Asunción¹,Jaén Pedro¹,Blauvelt Andrew³,González-Cantero Álvaro¹²

Affiliation:

1. Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS . Madrid , Spain

2. Facultad de Medicina, Universidad Francisco de Vitoria , Pozuelo de Alarcón , Spain

3. Oregon Medical Research Center , Portland, OR , USA

Abstract

This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of < 1.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad361/54705717/llad361.pdf

Reference3 articles.

1. Defining and treating moderate plaque psoriasis: a dermatologist survey;Knuckles;J Dermatol Treat,2018

2. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks;Reich;Br J Dermatol,2020

3. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR);Blauvelt;Br J Dermatol,2017